Hi ohm20, first off want to thank you for informat
Post# of 148628
Being they didnt have the exclusion for the ccr5 delta 32 double allele deletion, this potentially caused less ccr5 receptors to be available for leronlimab to inhibit and possibly showed a lower efficacy in the overall trial? In other words, its possible if this exclusion was in place, the results could have shown better efficacy?